297 related articles for article (PubMed ID: 23538480)
1. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.
López-Serrano P; Pérez-Calle JL; Sánchez-Tembleque MD
World J Gastroenterol; 2013 Mar; 19(9):1342-8. PubMed ID: 23538480
[TBL] [Abstract][Full Text] [Related]
2. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.
Gisbert JP; Chaparro M; Esteve M
Aliment Pharmacol Ther; 2011 Mar; 33(6):619-33. PubMed ID: 21416659
[TBL] [Abstract][Full Text] [Related]
3. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
[TBL] [Abstract][Full Text] [Related]
5. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
7. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
[TBL] [Abstract][Full Text] [Related]
8. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
9. [Reactivation of chronic hepatitis B].
Šperl J
Vnitr Lek; 2013 Jul; 59(7):591-6. PubMed ID: 23909265
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients].
von Wagner M; Zeuzem S
Dtsch Med Wochenschr; 2009 Feb; 134(6):255-8. PubMed ID: 19180418
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
Mori S; Fujiyama S
World J Gastroenterol; 2015 Sep; 21(36):10274-89. PubMed ID: 26420955
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.
Manzano-Alonso ML; Castellano-Tortajada G
World J Gastroenterol; 2011 Mar; 17(12):1531-7. PubMed ID: 21472116
[TBL] [Abstract][Full Text] [Related]
16. Occult HBV infection in the oncohematological setting.
Sagnelli C; Macera M; Pisaturo M; Zampino R; Coppola M; Sagnelli E
Infection; 2016 Oct; 44(5):575-82. PubMed ID: 27076347
[TBL] [Abstract][Full Text] [Related]
17. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.
Axiaris G; Zampeli E; Michopoulos S; Bamias G
World J Gastroenterol; 2021 Jul; 27(25):3762-3779. PubMed ID: 34321842
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression and HBV reactivation.
Shouval D; Shibolet O
Semin Liver Dis; 2013 May; 33(2):167-77. PubMed ID: 23749673
[TBL] [Abstract][Full Text] [Related]
20. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
